A novel co-stimulatory receptor composed of the scFv of the TR2 mAb combined with a 4-1BB endodomain successfully protected anti-MUC1 CAR T-cells from MDSC immunosuppression and promoted superior anti-tumor activity in breast cancer models [52]. Here, MUC1 is linked to neoplasm.